deSouza, NM;
Winfield, JM;
Waterton, JC;
Weller, A;
Papoutsaki, M-V;
Doran, SJ;
Collins, DJ;
... Liu, Y; + view all
(2017)
Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives.
European Radiology
, 28
(3)
pp. 1118-1131.
10.1007/s00330-017-4972-z.
Preview |
Text
10.1007%2Fs00330-017-4972-z.pdf - Published Version Download (1MB) | Preview |
Abstract
For body imaging, diffusion-weighted MRI may be used for tumour detection, staging, prognostic information, assessing response and follow-up. Disease detection and staging involve qualitative, subjective assessment of images, whereas for prognosis, progression or response, quantitative evaluation of the apparent diffusion coefficient (ADC) is required. Validation and qualification of ADC in multicentre trials involves examination of i) technical performance to determine biomarker bias and reproducibility and ii) biological performance to interrogate a specific aspect of biology or to forecast outcome. Unfortunately, the variety of acquisition and analysis methodologies employed at different centres make ADC values non-comparable between them. This invalidates implementation in multicentre trials and limits utility of ADC as a biomarker. This article reviews the factors contributing to ADC variability in terms of data acquisition and analysis. Hardware and software considerations are discussed when implementing standardised protocols across multi-vendor platforms together with methods for quality assurance and quality control. Processes of data collection, archiving, curation, analysis, central reading and handling incidental findings are considered in the conduct of multicentre trials. Data protection and good clinical practice are essential prerequisites. Developing international consensus of procedures is critical to successful validation if ADC is to become a useful biomarker in oncology.
| Type: | Article |
|---|---|
| Title: | Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s00330-017-4972-z |
| Publisher version: | https://doi.org/10.1007/s00330-017-4972-z |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Radiology, Nuclear Medicine & Medical Imaging, Diffusion-weighted MRI, Multicentre trials, Quality assurance, Quantitation, Standardization, INTRAVOXEL INCOHERENT MOTION, CELL LUNG-CANCER, COEFFICIENT MEASUREMENT, ADC MEASUREMENTS, CLINICAL-TRIALS, TUMOR HETEROGENEITY, ABDOMINAL ORGANS, WATER DIFFUSION, RECTAL-CANCER, SPIN-ECHO |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Department of Imaging |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10047602 |
Archive Staff Only
 |
View Item |
